

## 20191025 FOI ref 333-1920 Request for the Number of Patients Treated

1. Please complete the number of patients treated with Synagis (palivizumab) in the grid below. Please note that the total number of patients (A to E) in each column must add to total patients in the last row in the corresponding column.

Patients / babies treated with Synagis in the last three years	Total number patients (with or without treatment with Palivizumab) <u>April 2018 to March 2019</u>	Total number patients (with or without treatment with Palivizumab) <u>April 2017 to March 2018</u>	Total number patients (with or without treatment with Palivizumab) <u>April 2016 to March 2017</u>
A. Total number of patients with BPD / CLD diagnosis	24	37	25
B. Total number of patients with CHD diagnosis	0	0	<5
C. Total number of <29wga (without BPD/CHD diagnosis)	34	20	33
D. Total number of multiple births immunised (without BPD/CHD diagnosis)	0	0	0
E. Other patients (please specify: _____)			
Total number of patients <sup>1</sup>	58	57	59

BPD: bronchopulmonary dysplasia; CLD: Chronic Lung Disease; CHD: congenital heart disease

**\*NOTE These figures are taken from BadgerNet. They give the number babies under 29 weeks with and without BPD each year NOT the numbers of babies treated with Palivizumab**

2. Please advise which OPCS codes are used within your Trust to code respiratory syncytial virus (RSV) prophylaxis treatment.

Code Description	Used within Trust to indicate patient received RSV prophylaxis treatment? Yes/No
X86.5 Respiratory syncytial virus prevention drugs band 1	The Trust uses both codes
X44.2 Intramuscular injection of vaccine	The Trust uses both codes
Other (if not listed above, please specify code(s)):	

3. If your Trust does not provide RSV prophylaxis treatment and you refer your patients to another Trust, please state to which Trust(s) patients are referred.

**Not applicable**

<sup>1</sup> Total patients treated with Synagis in each of the last 3 years

We are required to pass on to our client details of any Adverse events and Product Complaints pertaining to their products that are mentioned during this research. If this happens, we will need to collect details and report the event, even if it has already been reported by you directly to the company or the regulatory authorities using the MHRA's 'Yellow Card' system. You will be asked whether you consent to us passing your details to the client company's drug safety department for their follow up, but you may choose to remain anonymous. This will have no impact on the confidentiality and anonymity associated with the research itself.

Adverse events should be reported.

Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/>

Adverse events should also be reported to AbbVie on [UK\\_PVVendor@abbvie.com](mailto:UK_PVVendor@abbvie.com)

FOI ref 333-1920